Management of relapsed/refractory mantle cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Mantle cell lymphoma (MCL) management has evolved significantly.
• Relapsed/refractory MCL presents ongoing therapeutic challenges.

Purpose of the Study:

• To review current evidence on managing relapsed/refractory MCL.
• To outline novel therapeutics developed over the past two decades.
• To discuss future treatment strategies.

Main Methods:

• Comprehensive literature review of novel therapeutics for MCL.
• Analysis of treatment outcomes including response rates and survival.
• Evaluation of emerging therapies and combination strategies.

Main Results:

• Novel therapies, particularly covalent Bruton Tyrosine Kinase inhibitors (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy, have dramatically increased overall response rates, complete response rates, duration of responses, and life expectancy.
• Emerging options like non-covalent BTKi, antibody-drug conjugates, Bcl-2 inhibitors, and bispecific antibodies show promise for progressive disease post-BTKi or CAR-T.

Conclusions:

• Current novel therapies have substantially improved outcomes for relapsed/refractory MCL.
• Future research should focus on optimal sequencing and combinations of therapies.
• Prioritizing curative potential in treatment strategies is essential.